Home

Epperly Melissa B,

CIK 1807359 · Chief Financial Officer · last filed 2026-07-21

Epperly Melissa B, is a Chief Financial Officer who has filed 57 SEC Form 4 insider transactions across 5 companies since 2020. The most recent filing, for ROIV, was dated Jul 21, 2026. Across all open-market trades the lifetime net is −$5.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.3M across reported positions. 23 SEC filings were submitted jointly with Roivant Sciences Ltd.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.28M

Companies

5

Total Filings

57

Lifetime Open-Market Net

-$4.97M

Filer Profile

Reported Address
101 WEST HAMPTON ROAD
PHILADELPHIA, PA 19118
Related Filers
Roivant Sciences Ltd. — 23 joint filings, latest 2026-07-21
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ROIV Director 17,017 $40.82 $694.6K -$1.81M 18 2026-07-21
NAUT Director — $1.02 — $0 5 2026-06-22
ZNTL Chief Financial Officer 451,449 $3.51 $1.58M -$3.15M 23 2024-02-12
Roivant Sciences Ltd. (ROIVW) Delisted Director 1,280 $2.75 $3.5K $0 2 2023-07-06
Kinnate Biopharma Inc. (KNTE) Delisted Director — $2.65 — $0 3 2023-06-13

Recent Filings

57 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-21 ROIV Grant (A) +543 $0 EDGAR
2026-07-01 ROIV Mixed — -$531.1K EDGAR
2026-06-29 ROIV Notice (144) −17,750 -$604.7K EDGAR
2026-06-22 NAUT Grant (A) — $0 EDGAR
2026-04-21 ROIV Grant (A) +670 $0 EDGAR
2026-03-18 ROIV Sell (S) −41,861 -$1.20M EDGAR
2026-03-16 ROIV Notice (144) −41,861 -$1.20M EDGAR
2026-01-22 ROIV Mixed +761 -$1.2K EDGAR
2025-10-22 ROIV Grant (A) +1,056 $0 EDGAR
2025-09-12 ROIV Mixed +12,863 -$22.9K EDGAR
Showing 1–10 of 57
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.